
Revvity Inc (RVTY) Stock Forecast & Price Target
Revvity Inc (RVTY) Analyst Ratings
Bulls say
Revvity exhibits a strong upward trajectory in growth, underpinned by a strategic shift to IGRA testing, which is expected to increase market share by several basis points annually. The company has enhanced its financial profile through the successful integration of high-growth segments, including software solutions and a leading life sciences reagents franchise, which altogether enhance profitability and cross-selling opportunities. Furthermore, ongoing improvements in margins, driven by operational leverage and substantial topline growth, position Revvity favorably to capitalize on increasing demand within its key markets.
Bears say
Revvity's financial outlook is negatively impacted by significant declines in its China operations, particularly in the Immunodiagnostics segment, which decreased by an unspecified double-digit percentage in the second quarter of 2025, contributing to an overall revenue drop of mid-single digits. The company faces risks from poor economic conditions and potential funding cuts, which could lead to decreased customer demand for its offerings, thereby affecting growth and market share. Additionally, macroeconomic factors such as inflation, product shortages, and labor issues could further disrupt Revvity's supply chain, hampering its ability to deliver products effectively.
This aggregate rating is based on analysts' research of Revvity Inc and is not a guaranteed prediction by Public.com or investment advice.
Revvity Inc (RVTY) Analyst Forecast & Price Prediction
Start investing in Revvity Inc (RVTY)
Order type
Buy in
Order amount
Est. shares
0 shares